This was shown in a retrospective analysis of a large, randomized, placebo-controlled trial in which patients who achieved RVR had an SVR rate of approximately 90% regardless of whether they received peginterferon alfa and
ribavirin, standard interferon and
ribavirin, or peginterferon alfa monotherapy. In addition, the likelihood of SVR patients with genotype 1 infection who achieve an RVR does not appear to be affected by shortening the duration or reducing the dose of ribavirin.